Functional imaging in primary tumour‐induced osteomalacia: relative performance of FDG PET/CT vs somatostatin receptor‐based functional scans: a series of nine patients
- 12 March 2014
- journal article
- Published by Wiley in Clinical Endocrinology
- Vol. 81 (1), 31-37
- https://doi.org/10.1111/cen.12426
Abstract
Localization of phosphatonin-producing mesenchymal tumours in patients with primary tumour-induced osteomalacia (pTIO) is challenging. Functional imaging plays an important role in the localization of these tumours. We studied the relative performance of different functional imaging modalities ((18) F-FDG PET/CT, (99) Tc-HYNIC-TOC SPECT/CT and (68) Ga-DOTATATE PET/CT) in tumour localization in cases of pTIO. Retrospective chart evaluation of 16 patients with confirmed TIO treated from 2006 to 2013 was conducted in a tertiary care referral centre. Of 16, nine patients had pTIO. In these nine, the positivity rates of different functional imaging modalities were 50% for (18) F-FDG PET/CT (four of eight patients), 100% for (99) Tc-HYNIC-TOC SPECT/CT (six of six patients) and 100% for (68) Ga-DOTATATE PET/CT (seven of seven patients). Of nine patients, six were subjected to both the (99) Tc-HYNIC-TOC SPECT/CT and (68) Ga-DOTATATE PET/CT and all of them showed coregistration on the two scans. In patients with pTIO, the somatostatin receptor-based functional scans performed better than (18) F-FDG PET/CT in tumour localization. Amongst the somatostatin receptor-based scans, (99) Tc-HYNIC-TOC SPECT/CT and (68) Ga-DOTATATE PET/CT performed equally well for localization of tumours.Keywords
This publication has 15 references indexed in Scilit:
- Oncogenic Osteomalacia Caused by Renal Cell CarcinomaJournal of Clinical Endocrinology & Metabolism, 2013
- Advanced prostate cancer as a cause of oncogenic osteomalacia: an underdiagnosed conditionSupportive Care in Cancer, 2012
- Tumor-induced osteomalacia: An important cause of adult-onset hypophosphatemic osteomalacia in China: Report of 39 cases and review of the literatureJournal of Bone and Mineral Research, 2012
- Tumor-induced osteomalaciaEndocrine-Related Cancer, 2011
- Expression Analysis of Fibroblast Growth Factor-23, Matrix Extracellular Phosphoglycoprotein, Secreted Frizzled-Related Protein-4, and Fibroblast Growth Factor-7: Identification of Fibroblast Growth Factor-23 and Matrix Extracellular Phosphoglycoprotein as Major Factors Involved in Tumor-Induced OsteomalaciaEndocrine Practice, 2008
- The Roles of Specific Genes Implicated as Circulating Factors Involved in Normal and Disordered Phosphate Homeostasis: Frizzled Related Protein-4, Matrix Extracellular Phosphoglycoprotein, and Fibroblast Growth Factor 23Endocrine Reviews, 2006
- Oncogenic osteomalacia: Diagnostic importance of fibroblast growth factor 23 and F-18 fluorodeoxyglucose PET/CT SCAN for the diagnosis and follow-up in one caseBone, 2005
- Octreotide Therapy for Tumor-Induced OsteomalaciaThe New England Journal of Medicine, 2001
- Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or ricketsCancer, 1987
- The assessment of phosphate reabsorptionClinica Chimica Acta; International Journal of Clinical Chemistry, 1969